Portal de Periódicos da CAPES

Prolactin Release in Children Treated With Risperidone

2007; Lippincott Williams & Wilkins; Volume: 27; Issue: 1 Linguagem: Inglês

10.1097/jcp.0b013e31802e68d5

1533-712X

Pieter W. Troost, Bertine Lahuis, Mirjam H. A. Hermans, Jan K. Buitelaar, Hermán van Engeland, Lawrence David Scahill, Ruud B. Minderaa, Pieter J. Hoekstra,

Pituitary Gland Disorders and Treatments

Little is known about the role of CYP2D6 polymorphism in risperidone-induced prolactin release in children.Twenty-five children (aged 5-15 years) with pervasive developmental disorders were genotyped for CYP2D6 polymorphisms. Serum prolactin, risperidone, and 9-hydroxyrisperidone were assessed at baseline and after 8 weeks of risperidone treatment (mean dosage, 0.06 +/- 0.03 mg/kg/d). After 24 weeks of treatment, prolactin was measured in a subsample of 15 children. Adverse effects were evaluated using a clinician-rated survey.Mean +/- SD prolactin levels increased from 7.8 +/- 8.0 ng/mL at baseline to 33.2 +/- 12.8 ng/mL at week 8 (P < 0.001), with a slight decrease to 28.8 +/- 13.6 ng/mL at week 24. At week 8, serum prolactin level was positively correlated with dose per kilogram (r = 0.648, P < 0.001), number of functional CYP2D6 genes (J = 2.117, P = 0.034), and serum 9-hydroxyrisperidone concentration (r = 0.664, P = 0.001) and was negatively correlated with the risperidone/9-hydroxyrisperidone ratio (r = -0.571, P = 0.004) but not with risperidone concentration (r = -0.243, P = 0.264) nor age (r = 0.072, P = 0.733). Prolactin elevation was not associated with adverse effects.Low-to-intermediate doses of risperidone induced a 4-fold prolactin increase in children without a clear development of tolerance up to 6 months. CYP2D6 ultrarapid metabolism may be a risk factor for more pronounced prolactin elevation.